Drug Profile


Alternative Names: 256U; 256U87; BW 256; BW 256U; Talavir; Valacyclovir; Valherpes; Valtrex; Vapridol; Virval; Zelitrex

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals; Branched-chain amino acids; Essential amino acids; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cytomegalovirus infections; Herpes simplex virus infections; Herpes zoster; Herpesvirus infections

Most Recent Events

  • 03 Jun 2015 No recent reports on development identified - Phase-III for Herpes simplex virus infections (Prevention) in Japan (PO)
  • 01 Mar 2015 GlaxoSmithKline completes a phase II trial for Hepatitis C in USA (NCT01580995)
  • 13 Dec 2013 Generic equivalent available in Japan for Viral infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top